Trial Profile
Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Determine the Efficacy and Safety of Vedolizumab in Prevention of Endoscopic Recurrence of Crohn's Disease in Patients with Ileo-colonic Surgical Resection and Ileocolonic Anastamosis : REPREVIO (recurrence prevention with Entyvio)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Nov 2023
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Acronyms REPREVIO
- 17 Oct 2023 Results assessing the value of fecal cal-protectin (FC) in a prospective cohort of patients enrolled in the REPREVIO trial, presented at the 31st United European Gastroenterology Week.
- 31 Jan 2023 Status changed to completed.
- 15 Jul 2016 New trial record